Chemomab Therapeutics Aligns Leadership Incentives With Shareholders

TipRanksNov 19 05:50

Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 16 04:31 · Ratings

Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11

Futu NewsNov 16 03:31 · Ratings

Chemomab Therapeutics Analyst Ratings

BenzingaNov 15 23:53 · Ratings

Express News | Chemomab Therapeutics Ltd. : Oppenheimer Cuts Target Price to $11 From $13

BreakingsNov 15 21:27

Chemomab Therapeutics Q3 2024 GAAP EPS $(0.20) Misses $(0.01) Estimate

BenzingaNov 14 20:07